- Insider Monkey•2 days ago
Apart from technology, if there ever was a sector that short sellers were afraid to touch for fear of being squeezed out vehemently, it has to be biotech. The remarkable rally that the sector saw in the years following the financial crisis caused even the most bearish of bears to change their thesis on it […]
- Investopedia•5 days ago
Xoma received preliminary approval to initiate a Phase 2 clinical study of its Xoma 358 drug to treat children over age 2 with hyperinsulinism in the UK.
- GlobeNewswire•7 days agoXOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism
BERKELEY, Calif., Oct. 19, 2016-- XOMA Corporation, a leader in the discovery and development of therapeutic antibodies, announced today the United Kingdom’ s Medicines and Healthcare Products Regulatory ...
XOMA Corporation (XOMA)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Day's Range||5.12 - 5.37|
|52wk Range||0.34 - 7.33|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||23.63|
|Avg Vol (3m)||806,375|
|Dividend & Yield||N/A (N/A)|